Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (ACRS)
NASDAQ:ACRS
Total Valuation
Aclaris Therapeutics has a market cap or net worth of $193.91M. The enterprise value is $76.62M.
Market Cap$193.91M
Enterprise Value$76.62M
Share Statistics
Aclaris Therapeutics has 108,332,214 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding108,332,214
Owned by Insiders2.95%
Owned by Institutions46.25%
Financial Efficiency
Aclaris Therapeutics’s return on equity (ROE) is -0.85 and return on invested capital (ROIC) is -74.82%.
Return on Equity (ROE)-0.85
Return on Assets (ROA)-0.60
Return on Invested Capital (ROIC)-74.82%
Return on Capital Employed (ROCE)-0.75
Revenue Per Employee306.89K
Profits Per Employee-2.17M
Employee Count61
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aclaris Therapeutics is ―. Aclaris Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value1.23
Price to FCF―
Price to Operating Cash Flow-20.86
PEG Ratio―
Income Statement
In the last 12 months, Aclaris Therapeutics had revenue of 18.72M and earned -132.06M in profits. Earnings per share was -1.71.
Revenue18.72M
Gross Profit15.93M
Operating Income-141.93M
Pretax Income-132.06M
Net Income-132.06M
EBITDA-51.72M
Earnings Per Share (EPS)-1.71
Cash Flow
In the last 12 months, operating cash flow was -9.99M and capital expenditures -35.87M, giving a free cash flow of -45.86M billion.
Operating Cash Flow-9.99M
Free Cash Flow-45.86M
Free Cash Flow per Share-0.42
Dividends & Yields
Aclaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.53
52-Week Price Change44.63%
50-Day Moving Average1.58
200-Day Moving Average2.00
Relative Strength Index (RSI)58.84
Average Volume (3m)1.24M
Important Dates
Aclaris Therapeutics upcoming earnings date is Nov 5, 2025, Before Open (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateNov 5, 2025
Ex-Dividend Date―
Financial Position
Aclaris Therapeutics as a current ratio of 3.99, with Debt / Equity ratio of 1.80%
Current Ratio3.99
Quick Ratio3.99
Debt to Market Cap<0.01
Net Debt to EBITDA0.42
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aclaris Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Aclaris Therapeutics EV to EBITDA ratio is -3.28, with an EV/FCF ratio of -8.40.
EV to Sales9.07
EV to EBITDA-3.28
EV to Free Cash Flow-8.40
EV to Operating Cash Flow-8.45
Balance Sheet
Aclaris Therapeutics has $99.81M in cash and marketable securities with $2.37M in debt, giving a net cash position of -$97.44M billion.
Cash & Marketable Securities$99.81M
Total Debt$2.37M
Net Cash-$97.44M
Net Cash Per Share-$0.90
Tangible Book Value Per Share$2.01
Margins
Gross margin is 24.18%, with operating margin of -758.18%, and net profit margin of -705.48%.
Gross Margin24.18%
Operating Margin-758.18%
Pretax Margin-705.48%
Net Profit Margin-705.48%
EBITDA Margin-276.28%
EBIT Margin-280.59%
Analyst Forecast
The average price target for Aclaris Therapeutics is $9.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.20
Price Target Upside425.71% Upside
Analyst ConsensusStrong Buy
Analyst Count5
Revenue Growth Forecast-47.56%
EPS Growth Forecast-65.54%